Originally published as JCO Early Release 10.1200/JCO.2005.03.2375 on January 23 2006

This Article Full Text Full Text (PDF) Supplementary Data Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanchez-Carbayo, M. Articles by Cordon-Cardo, C. Search for Related Content PubMed PubMed Citation Articles by Sanchez-Carbayo, M. Articles by Cordon-Cardo, C.

Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays

From the Division of Molecular Pathology and Computational Biology Center Memorial Sloan-Kettering Cancer Center, New York, NY; and the Centre de Regulacio Genomica, Barcelona, Spain

Address reprint requests to Marta Sanchez-Carbayo, PhD, Tumor Markers Group, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncológicas, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain; e-mail: marta.sanchez-carbayo{at}cnio.es

PURPOSE: Bladder cancer is a common malignancy characterized by a poor clinical outcome when tumors progress into invasive disease. We sought to define genetic signatures characteristic of aggressive clinical behavior in advanced bladder tumors.

METHODS: Oligonucleotide arrays were utilized to analyze the transcript profiles of 105 bladder tumors: 33 superficial, 72 invasive lesions, and 52 normal urothelium. Hierarchical clustering and supervised algorithms were used to classify and stratify bladder tumors on the basis of stage, node metastases, and overall survival. Immunohistochemical analyses on bladder cancer tissue arrays (n = 294 cases) served to validate associations between marker expression, staging and outcome.

RESULTS: Hierarchical clustering classified normal urothelium, superficial, and invasive tumors with 82.2% accuracy, and stratified bladder tumors on the basis of clinical outcome. Predictive algorithms rendered an 89%-correct rate for tumor staging using genes differentially expressed between superficial and invasive tumors. Accuracies of 82% and 90% were obtained for predicting overall survival when considering all patients with bladder cancer or only patients with invasive disease, respectively. A genetic profile consisting of 174 probes was identified in those patients with positive lymph nodes and poor survival. Two independent Global Test runs confirmed the robust association of this profile with lymph node metastases (P = 7.3^–13) and overall survival (P = 1.9^–14) simultaneously. Immunohistochemical analyses on tissue arrays sustained the significant association of synuclein with tumor staging and clinical outcome (P = .002).

CONCLUSION: Gene profiling provides a genomic-based classification scheme of diagnostic and prognostic utility for stratifying advanced bladder cancer. Identification of this poor outcome profile could assist in selecting patients who may benefit from more aggressive therapeutic intervention.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				A. Holyoake, P. O'Sullivan, R. Pollock, T. Best, J. Watanabe, Y. Kajita, Y. Matsui, M. Ito, H. Nishiyama, N. Kerr, et al. Development of a Multiplex RNA Urine Test for the Detection and Stratification of Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., February 1, 2008; 14(3): 742 - 749. [Abstract] [Full Text] [PDF]

				M. Sanchez-Carbayo, N. D. Socci, L. Richstone, M. Corton, N. Behrendt, J. Wulkfuhle, B. Bochner, E. Petricoin, and C. Cordon-Cardo Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression Am. J. Pathol., November 1, 2007; 171(5): 1650 - 1658. [Abstract] [Full Text] [PDF]

				J. K. Lee, D. M. Havaleshko, H. Cho, J. N. Weinstein, E. P. Kaldjian, J. Karpovich, A. Grimshaw, and D. Theodorescu A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery PNAS, August 7, 2007; 104(32): 13086 - 13091. [Abstract] [Full Text] [PDF]

				F. Maluf, C Cordon-Cardo, D. Verbel, J. Satagopan, M. Boyle, H Herr, and D. Bajorin Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment Ann. Onc., November 1, 2006; 17(11): 1677 - 1686. [Abstract] [Full Text] [PDF]

				C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889. [Full Text] [PDF]